Anti-SPARC 抗体 [EPR20121]
Anti-SPARC antibody [EPR20121]
- RabMAb
- Recombinant
- KO Validated
- 詳細を見る
5
(2 Reviews)
|
(9 Publications)
Rabbit Recombinant Monoclonal SPARC antibody. Suitable for IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 9 publications.
別名を表示する
ON, SPARC, Basement-membrane protein 40, Osteonectin, Secreted protein acidic and rich in cysteine, BM-40
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-SPARC antibody [EPR20121] (AB207743)
Intracellular flow cytometric analysis of 4% paraformaldehyde-fixed A-375 (Human malignant melanoma cell line) cells labeling SPARCwith ab207743 at 1/70 dilution (red) compared with a rabbit monoclonal IgG isotype control (ab172730; black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti rabbit IgG (Alexa Fluor® 488) at 1/2000 dilution was used as the secondary antibody.
- IP
Supplier Data
Immunoprecipitation - Anti-SPARC antibody [EPR20121] (AB207743)
SPARC was immunoprecipitated from 0.35 mg of A-375 (Human malignant melanoma cell line) whole cell lysate with ab207743 at 1/40 dilution.
Western blot was performed from the immunoprecipitate using ab207743 at 1/1000 dilution.
VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.
Lane 1 : A-375 whole cell lysate, 10μg (Input).
Lane 2 : ab207743 IP in A-375 whole cell lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab207743 in A-375 whole cell lysate.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 3 minutes.
All lanes:
Immunoprecipitation - Anti-SPARC antibody [EPR20121] (ab207743)
Predicted band size: 35 kDa
Observed band size: 43 kDa
false
- WB
Supplier Data
Western blot - Anti-SPARC antibody [EPR20121] (AB207743)
Blocking/Dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-SPARC antibody [EPR20121] (ab207743) at 1/1000 dilution
Lane 1:
Human serum at 10 µg
Lane 2:
Human brain lysate at 10 µg
Secondary
All lanes:
Western blot - VeriBlot for IP Detection Reagent (HRP) (<a href='/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/4000 dilution
Predicted band size: 35 kDa
Observed band size: 43 kDa
false
Exposure time: 5s
- WB
Supplier Data
Western blot - Anti-SPARC antibody [EPR20121] (AB207743)
Blocking/Dilution buffer : 5% NFDM/TBST.
Exposure time : Lane 1 : 30 seconds; Lane 2/3 : 3 minutes.
The observed molecular weight is consistent with what has been described in the literature (PMID : 18442048).
All lanes:
Western blot - Anti-SPARC antibody [EPR20121] (ab207743) at 1/1000 dilution
Lane 1:
SH-SY5Y (Human neuroblastoma cell line from bone marrow) whole cell lysate at 20 µg
Lane 2:
A-375 (Human malignant melanoma cell line) whole cell lysate at 20 µg
Lane 3:
Human bone giant cell tumor lysate at 20 µg
Secondary
Lanes 1 - 2:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Lane 3:
Western blot - VeriBlot for IP Detection Reagent (HRP) (<a href='/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/4000 dilution
Predicted band size: 35 kDa
Observed band size: 43 kDa
false
- WB
Lab
Western blot - Anti-SPARC antibody [EPR20121] (AB207743)
Lanes 1 - 2 : Merged signal (red and green). Green - ab207743 observed at 35 kDa. Red - loading control, ab130007, observed at 130 kDa.
ab207743 was shown to recognize SPARC in wild-type HAP1 cells as signal was lost at the expected MW in SPARC knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and SPARC knockout samples were subjected to SDS-PAGE. ab207743 and ab130007 (Mouse anti-Vinculin loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-SPARC antibody [EPR20121] (ab207743) at 1/1000 dilution
Lane 1:
Wild-type HAP1 whole cell lysate at 20 µg
Lane 2:
SPARC knockout HAP1 whole cell lysate at 20 µg
Predicted band size: 35 kDa
Observed band size: 35 kDa
false
関連する標識済み抗体及び組成の異なる製品 (3)
-
Anti-SPARC antibody [EPR20121] - BSA and Azide free
-
Anti-SPARC antibody [EPR20121] - BSA and Azide free (Capture)
-
Anti-SPARC antibody [EPR20121] - Low endotoxin, Azide free
Reactivity data
製品の詳細
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
出荷温度及び保存条件
製品の状態
精製方法
バッファー組成
出荷温度
短期保存期間
短期保存温度
長期保存温度
分注に関する情報
保管に関する情報
補足情報
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
SPARC impacts processes related to cell communication and matrix dynamics. It does not form part of large complexes but functions through interactions with matrix molecules and receptors. SPARC regulates collagen fibrillogenesis and influences the bioavailability of growth factors. It further affects angiogenesis through its ability to alter cellular adhesion and spreading which impacts vascular development and repair processes.
Pathways
SPARC integrates into regulatory cascades such as the WNT signaling and TGF-β pathways. These pathways are essential for cellular growth repair and differentiation. In the context of the TGF-β signaling pathway SPARC modulates interactions with proteins like integrins and collagens impacting fibrotic processes and matrix assembly.
製品プロトコール
- Visit the General protocols
- Visit the Troubleshooting
ターゲットの情報
文献 (9)
Recent publications for all applications. Explore the full list and refine your search
APL bioengineering 9:036115 PubMed40895767
2025
Applications
Unspecified application
Species
Unspecified reactive species
iScience 27:111437 PubMed39717085
2024
Applications
Unspecified application
Species
Unspecified reactive species
Regenerative therapy 25:290-301 PubMed38318480
2024
Applications
Unspecified application
Species
Unspecified reactive species
Neoplasma 69:1101-1107 PubMed35951457
2022
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 21:485 PubMed33968201
2021
Applications
Unspecified application
Species
Unspecified reactive species
Phytotherapy research : PTR 34:591-600 PubMed32011040
2020
Applications
Unspecified application
Species
Unspecified reactive species
Journal of gastroenterology and hepatology 34:1860-1868 PubMed31041810
2019
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 15:4323-4329 PubMed29541199
2018
Applications
Unspecified application
Species
Unspecified reactive species
Oncotarget 8:104508-104524 PubMed29262657
2017
Applications
Unspecified application
Species
Unspecified reactive species
Abcam product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com